var data={"title":"Tacrolimus (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tacrolimus (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390450?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tacrolimus-systemic-drug-information\" class=\"drug drug_general\">see &quot;Tacrolimus (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=tacrolimus-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tacrolimus (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559505\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancies and serious infection:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections and the possible development of malignancies such as lymphoma and skin cancer may result from immunosuppression and may lead to hospitalization or death.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\"> Only health care providers experienced in immunosuppressive therapy and management of organ transplant patients should prescribe tacrolimus. Manage patients receiving the drug in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mortality in liver transplantation (Astagraf XL):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased mortality in female transplant patients with Astagraf XL. Astagraf XL is not approved for use in liver transplantation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559510\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Astagraf XL;</li>\n      <li>Envarsus XR;</li>\n      <li>Hecoria [DSC];</li>\n      <li>Prograf</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559511\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Advagraf;</li>\n      <li>Prograf</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527287\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527364\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tacrolimus-systemic-drug-information\" class=\"drug drug_general\">see &quot;Tacrolimus (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Extended-release products (Astagraf XL and Envarsus XR) are not interchangeable or substitutable with immediate-release tacrolimus. In addition, the once-daily formulations (Astagraf XL and Envarsus XR) are not interchangeable with each other due to significantly different pharmacokinetic properties. Hecoria has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Younger children generally require higher maintenance doses on a mg/kg basis than older children, adolescents, or adults (Kim 2005; Montini 2006). Adjust initial dose to achieve desired target tacrolimus concentration; specific institutional protocols should be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Graft-vs-host disease (GVHD); prevention: </b>Limited data available; dosing regimens variable:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: Infants, Children, and Adolescents: IV: Initial: 0.03 mg/kg/day (based on lean body weight) as continuous IV infusion; begin prior to pretransplant (specific day varies with protocol); monitor serum drug concentrations and adjust dose accordingly; convert to oral formulation when tolerated (Offer 2015; Yanik 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent infusion: Children and Adolescents: IV: 0.015 mg/kg/dose every 12 hours as a 2-hour infusion. Treatment was initiated on day &minus;2 or day &minus;3 prior to transplant and continued until oral medication tolerated; dosing based on a descriptive study in 33 patients (median age: 10 years; range: 1.2 to 17 years); during the trial, no infusion related reactions were reported and no higher incidence of toxicity or adverse effects reported (Skeens 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nephrotic syndrome, steroid-resistant or steroid-dependent:</b> Limited data available: Children and Adolescents: Oral: Immediate release: Initial: 0.1 mg/kg/day divided every 12 hours; adjust to target serum concentration; the reported dose range (regardless of target serum concentration) is 0.06 to 0.19 mg/kg/day in divided doses every 12 hours (Bock 2013; Gulati 2012; Jahan 2015; KDIGO 2012). Goal tacrolimus concentration varies dependent upon type of nephrotic syndrome and patient characteristics; most frequently reported goal is 5 to 10 ng/mL (KDIGO 2012), largely based on experience from transplant data; however, some studies suggest targeting lower trough concentrations of 3 to 5 ng/mL (Bock 2013; Jahan 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplant, heart; prevention of rejection</b>: Limited data available: Infants, Children, and Adolescents: Dose should be individualized and titrated to target trough concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release: Initial: 0.1 to 0.3 mg/kg/day divided every 12 hours (Pollock-Barziv 2005; Singh 2016; Swenson 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.01 to 0.03 mg/kg/day as a continuous IV infusion (Groetzner 2005).<b> Note: </b>Limit parenteral use to patients unable to take enteral formulations; patients should be switched to an enteral dosage form as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplant, kidney; prevention of rejection</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Dose should be individualized and titrated to target trough concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: Limited data available: Children and Adolescents: Initial: 0.2 to 0.3 mg/kg/day divided every 12 hours (Filler 2005; KDIGO 2009; Kim 2005; Montini 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release: Astagraf XL: Adolescents &ge;16 years: Used in combination with corticosteroids and mycophenolate:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">With basiliximab induction: Initial: 0.15 to 0.2 mg/kg once daily; administer first dose prior to reperfusion or within 48 hours of transplant. Titrate to target trough concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Without basiliximab induction:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preoperative dose: 0.1 mg/kg once; administer within 12 hours prior to reperfusion</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postoperative dose: 0.2 mg/kg once daily; administer first postoperative dose at least 4 hours after preoperative dose and within 12 hours of reperfusion. Titrate to target trough concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from IV to extended release</i> (<i>Astagraf XL</i>): Administer the first oral extended-release dose 8 to 12 hours after discontinuation of IV tacrolimus</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from immediate release to extended release</i> (<i>Astagraf XL</i>): Limited data available: Initiate extended-release treatment in a 1:1 ratio (mg:mg) using previously established total daily dose of immediate release; based on experience in adult patients (Van Hooff 2012). Administer once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Limited data available: Infants, Children, and Adolescents: 0.06 mg/kg/day as a continuous IV infusion (Trompeter 2002). <b>Note: </b>Limit parenteral use to patients unable to take enteral formulations; patients should be switched to an enteral dosage form as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplant, liver; prevention of rejection</b>: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release: Initial: 0.15 to 0.2 mg/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.03 to 0.05 mg/kg/day as a continuous IV infusion. <b>Note: </b>Limit parenteral use to patients unable to take enteral formulations; patients should be switched to an enteral dosage form as soon as possible (initiate 8 to 12 hours after infusion is stopped).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dose conversion of different routes of administration: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion of IV continuous infusion to immediate-release oral: GVHD prophylaxis: </i>Limited data available: To convert from IV to oral dose (1:4 ratio): Multiply total daily IV dose by 4 and administer in 2 divided oral doses per day, every 12 hours; titrate to goal trough concentration (Yanik 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion of immediate-release oral to sublingual (using immediate-release capsule)</i>: Very limited data available: To convert from oral to sublingual dose (2:1 ratio): Divide oral dose by 2 for sublingual administration. Dosing based on experience in adult solid organ transplant recipients unable to tolerate enteral administration (Doligalski 2014; Tsapepas 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 0.075-0.2 mg/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Liver transplant: Initial: 0.1-0.15 mg/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Heart transplant: Initial: 0.075 mg/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kidney transplant: Initial: 0.2 mg/kg/day in combination with azathioprine or 0.1 mg/kg/day in combination with mycophenolate mofetil. Administer in 2 divided doses every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention of graft-vs-host disease (off-label use): Convert from IV to oral dose (1:4 ratio): Multiply total daily IV dose times 4 and administer in 2 divided oral doses per day, every 12 hours (Uberti, 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV continuous infusion: 0.01-0.05 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Liver or kidney transplant: Initial: 0.03-0.05 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Heart transplant: Initial: 0.01 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Graft-vs-host disease (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prevention: 0.03 mg/kg/day (based on lean body weight) as continuous infusion. Treatment should begin at least 24 hours prior to stem cell infusion and continued only until oral medication can be tolerated (Przepiorka, 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment: Initial: 0.03 mg/kg/day (based on lean body weight) as continuous infusion (Furlong, 2000; Przepiorka, 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal or hepatic impairment:</b> Patients with renal or hepatic impairment should receive the lowest dose in the recommended dosage range; further reductions in dose below these ranges may be required</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemodialysis:</b> Not removed by hemodialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564277\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hecoria: 0.5 mg [DSC], 1 mg [DSC], 5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prograf: 0.5 mg, 1 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Astagraf XL: 0.5 mg, 1 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prograf: 5 mg/mL (1 mL) [contains alcohol, usp, cremophor el]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Envarsus XR: 0.75 mg, 1 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559517\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29038337\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=tacrolimus-systemic-drug-information\" class=\"drug drug_general\">see &quot;Tacrolimus (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Prograf injection contains polyoxyl 60 hydrogenated castor oil (HCO-60)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50136484\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Hecoria has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099222\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Astagraf XL: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362199.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WslJQR48rpG4rf8i2Z0emrw==&amp;TOPIC_ID=16051\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362199.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527365\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Administration should begin no sooner than 6 hours post-transplant in liver and heart transplant patients; in kidney transplant patients the initial dose may be administered within 24 hours of transplant, but should be delayed until renal function has recovered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Administer with or without food; be consistent with timing and composition of meals if GI intolerance occurs and administration with food becomes necessary (per manufacturer); do not administer with grapefruit juice; do not administer within 2 hours before or after antacids. If dosed twice daily, doses should be 12 hours apart. If the morning and evening doses differ, the larger dose (differences are never &gt;0.5 to 1 mg) should be administered in the morning; however, some data suggests that the larger dose should be given in the evening since tacrolimus exposure may be reduced in the evening due to diurnal variation (Iwahori 2005; Min 1997; Park 2007). If dosed 3 times daily, separate doses by 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nasogastric tube</i>: If unable to swallow capsules, contents of immediate-release capsule(s) may be mixed with water and flushed through a nasogastric tube; clamp nasogastric tube for 30 to 60 minutes after administration (Taylor 2001). <b>Note: </b>If patient receiving an extended-release formulation, convert to an appropriate dose of the immediate release. Dosing for immediate-release capsules is not equivalent to dosing of Envarsus XR. When switching from Envarsus XR to immediate-release capsules for nasogastric administration, consider administering a 20% to 30% higher total daily dose of immediate-release tacrolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sublingual</i>\n      <i>:</i> Recommendations include opening capsules and applying contents under the tongue. Patient should be advised not to swallow for 5 to 15 minutes and eating or drinking anything for up to 30 minutes (Pennington 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Adolescents &ge;16 years and Adults: Administer on an empty stomach at least 1 hour before or 2 hours after a meal. Swallow whole; do not chew, crush, or divide. Take once daily in the morning at a consistent time each day. Missed doses may be taken up to 14 hours (15 hours for Envarsus XR) after scheduled time; if &gt;14 hours (&gt;15 hours for Envarsus XR), resume at next regularly scheduled time; do not double a dose to make up for a missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer by IV infusion as a continuous infusion (preferred) (generally over 24 hours) or may also be administered as an intermittent infusion given over 2 hours (Skeens 2012). Must be diluted prior to administration. Do not use PVC tubing when administering diluted solutions; polyvinyl chloride-free administration tubing should be used to minimize the potential for significant drug absorption onto the tubing; adsorption of the drug to PVC tubing may become clinically significant with low concentrations. Do not mix with solutions with a pH &ge;9 (eg, acyclovir or ganciclovir) due to chemical degradation of tacrolimus (use different ports in multilumen lines). Do not alter dose with concurrent T-tube clamping. Continue only until oral medication can be tolerated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133425\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564175\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Prior to dilution, store at 5&deg;C to 25&deg;C (41&deg;F to 77&deg;F). Following dilution, stable for 24 hours in D<sub>5</sub>W or NS in glass or polyethylene containers. Do not store in polyvinyl chloride containers since the polyoxyl 60 hydrogenated castor oil injectable vehicle may leach phthalates from polyvinyl chloride containers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Astagraf XL,  Envarsus XR, Prograf: Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hecoria: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527303\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Prograf (Oral, IV): Prevention of organ rejection in liver transplant recipients (FDA approved in pediatric patients [age not specified] and adults); prevention of organ rejection in heart and kidney transplant recipients (FDA approved in adults); has also been used in the prevention of graft-versus-host disease (GVHD) and treatment of steroid-resistant nephrotic syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Astagraf XL: Prevention of organ rejection in kidney transplant recipients in combination with other immunosuppressants (FDA approved in ages &ge;16 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Envarsus XR: Prevention of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulation, in combination with other immunosuppressants (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559508\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prograf may be confused with Gengraf, PROzac</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tacrolimus may be confused with everolimus, pimecrolimus, sirolimus, tamsulosin, temsirolimus</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The immediate release (Hecoria, Prograf) and extended release (Astagraf XL, Advagraf [Canadian product]) oral formulations are not interchangeable and are not substitutable.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559544\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, atrial fibrillation, atrial flutter, bradycardia, cardiac arrhythmia, cardiac failure, cerebral infarction, cerebral ischemia, chest pain, deep vein thrombophlebitis, deep vein thrombosis, ECG abnormality (QRS or ST segment or T wave), edema, flushing, hemorrhagic stroke, hypertension, hypertrophic cardiomyopathy, hypotension, ischemic heart disease, localized phlebitis, myocardial infarction, orthostatic hypotension, pericardial effusion, peripheral edema, peripheral vascular disease, phlebitis, syncope, tachycardia, thrombosis, vasodilatation, ventricular premature contractions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, abnormality in thinking, agitation, amnesia, anxiety, aphasia, ataxia, brain disease, carpal tunnel syndrome, chills, confusion, depression, dizziness, drowsiness, emotional lability, excessive crying, falling, fatigue, flaccid paralysis, hallucination, headache, hypertonia, hypoesthesia, insomnia, mental status changes, mood elevation, myasthenia, myoclonus, nervousness, neuropathy (including compression), neurotoxicity, nightmares, pain, paresis, paresthesia, peripheral neuropathy, psychosis, seizure, vertigo, voice disorder, writing difficulty</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, cellulitis, condyloma acuminatum, dermal ulcer, dermatitis (including fungal), dermatological reaction, diaphoresis, exfoliative dermatitis, pruritus, skin discoloration, skin photosensitivity, skin rash, tinea versicolor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, albuminuria, alkalosis, anasarca, Cushing's syndrome, decreased serum bicarbonate, decreased serum iron, dehydration, diabetes mellitus, gout, hirsutism, hypercalcemia, hypercholesterolemia, hyperkalemia, hyperphosphatemia, hypertriglyceridemia, hypervolemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, increased gamma-glutamyl transferase, increased lactate dehydrogenase, weight changes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, dyspepsia, aphthous stomatitis, cholangitis, colitis, constipation, delayed gastric emptying, diarrhea, duodenitis, dysphagia, enlargement of abdomen, esophagitis (including ulcerative), flatulence, gastric ulcer, gastritis, gastroenteritis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal perforation, hernia, hiccups, increased appetite, intestinal obstruction, nausea, oral candidiasis, pancreatic disease (pseudocyst), pancreatitis (including hemorrhagic and necrotizing), peritonitis, rectal disease, stomach cramps, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Anuria, bladder spasm, cystitis, dysuria, hematuria, nocturia, oliguria, proteinuria, toxic nephrosis, urinary frequency, urinary incontinence, urinary retention, urinary tract infection, urinary urgency, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, blood coagulation disorder, bruise, decreased prothrombin time, hemolytic anemia, hemorrhage, hypochromic anemia, hypoproteinemia, increased hematocrit, increased INR, Kaposi&rsquo;s sarcoma, leukocytosis, leukopenia, malignant neoplasm of bladder, malignant neoplasm of thyroid (papillary), neutropenia, pancytopenia, polycythemia, skin neoplasm, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, ascites, cholestatic jaundice, hepatic injury, hepatitis (including acute, chronic, and granulomatous), hyperbilirubinemia, increased serum alkaline phosphatase, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Graft complications</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess, infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, leg cramps, muscle spasm, muscle weakness of the extremities, myalgia, osteoporosis, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Amblyopia, blurred vision, conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Hearing loss, otalgia, otitis externa, otitis media, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure, hydronephrosis, increased blood urea nitrogen, increased serum creatinine, renal disease (BK nephropathy), renal function abnormality, renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Allergic rhinitis, asthma, atelectasis, cough, flu-like symptoms, pleural effusion, pneumothorax, pulmonary edema, respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, postoperative pain, postoperative wound complication, wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Adult respiratory distress syndrome, agranulocytosis, anaphylactoid reaction, anaphylaxis, angioedema, basal cell carcinoma, biliary tract disease (stenosis), blindness, cerebrovascular accident, coma, deafness, decreased serum fibrinogen, delirium, disseminated intravascular coagulation, dysarthria, graft versus host disease (acute and chronic), hemiparesis, hemolytic-uremic syndrome, hemorrhagic cystitis, hepatic cirrhosis, hepatic failure, hepatic necrosis, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatosplenic T-cell lymphomas, hepatotoxicity, hyperpigmentation, immune thrombocytopenia, interstitial pulmonary disease, leukemia, leukoencephalopathy, liver steatosis, lymphoproliferative disorder (post-transplant or related to Epstein-Barr virus), malignant lymphoma, malignant melanoma, multi-organ failure, mutism, optic atrophy, osteomyelitis, photophobia, polyarthritis, progressive multifocal leukoencephalopathy (PML), prolonged partial thromboplastin time, prolonged Q-T interval on ECG, pulmonary hypertension, pure red cell aplasia, quadriplegia, reversible posterior leukoencephalopathy syndrome, rhabdomyolysis, septicemia, squamous cell carcinoma, status epilepticus, Stevens-Johnson syndrome, supraventricular extrasystole, supraventricular tachycardia, thrombotic thrombocytopenic purpura, torsades de pointes, toxic epidermal necrolysis, urticaria, venous thrombosis, ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559526\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tacrolimus, polyoxyl 60 hydrogenated castor oil (HCO-60), or any other component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559527\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Injection: Hypersensitivity reactions, including anaphylaxis, have been reported with tacrolimus injection. Tacrolimus injection contains polyoxyl 60 hydrogenated castor oil (HCO-60), a castor oil derivative. HCO-60 is a solubilizer similar to polyoxyethylated castor oil (also known as polyoxyl 35 castor oil or Cremophor EL); polyoxyethylated castor oil is associated with hypersensitivity reactions (Nicolai 2012). Tacrolimus intravenous (IV) use should be limited to patients unable to take oral capsules. Monitor patient for a minimum of 30 minutes after initiation of infusion and then at frequent intervals; discontinue infusion if anaphylaxis occurs. Patients should be transitioned from IV to oral tacrolimus as soon as the patient can tolerate oral administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular: Myocardial hypertrophy has been reported; may be reversible with dose reduction or discontinuation. Prolongation of the QT/QTc and torsade de pointes may occur; avoid use in patients with congenital long QT syndrome. Consider obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus (post-transplant): The risk for new-onset diabetes and insulin-dependent post-transplant diabetes mellitus (PTDM) is increased with tacrolimus use after transplantation, including in patients without pretransplant history of diabetes mellitus. Insulin dependence may be reversible. Monitor blood glucose frequently. Risk is increased in African-American and Hispanic kidney transplant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal perforation: Gastrointestinal perforation may occur; all reported cases were considered to be a complication of transplant surgery or accompanied by infection, diverticulum, or malignant neoplasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Mild-to-severe hyperkalemia may occur; monitor serum potassium levels and avoid use of potassium-sparing diuretics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Hypertension may commonly occur; antihypertensive treatment may be necessary; avoid use of potassium-sparing diuretics due to risk of hyperkalemia. Concurrent use of calcium channel blockers may require tacrolimus dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections:<b> [US Boxed Warning]: Immunosuppressant agents, including tacrolimus, increase the risk of infection; the risk of developing bacterial, viral (including CMV), fungal, and protozoal infections, including opportunistic infections, is increased.</b> Infections may result in serious and fatal outcomes. Latent viral infections may be activated, including BK virus (associated with polyoma virus-associated nephropathy [PVAN]) and JC virus (associated with progressive multifocal leukoencephalopathy [PML]); may result in serious adverse effects. Immunosuppression increases the risk for CMV viremia and/or CMV disease; the risk of CMV disease is increased for patients who are CMV-seronegative prior to transplant and receive a graft from a CMV-seropositive donor. Monitor for development of infection; consider reduction in immunosuppression if PVAN, PML, CMV viremia and/or CMV disease occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Immunosuppressant agents, including tacrolimus, may be associated with the development of lymphoma and other malignancies (predominantly skin malignancies).</b> The risk for malignancies is related to intensity/duration of therapy. Limit or avoid sun and ultraviolet light exposure; use appropriate sun protection. Post-transplant lymphoproliferative disorder related to EBV infection has been reported in immunosuppressed organ transplant patients; risk highest in young children; use combination immunosuppressant therapy with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Nephrotoxicity (acute or chronic) may occur when used in high doses, in patients with impaired renal function, with other nephrotoxic drugs (eg, sirolimus, cyclosporine), or when administered concomitantly with CYP3A inhibitors (due to increased tacrolimus concentrations). Monitor renal function and consider dosage reduction if nephrotoxicity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Neurotoxicity may occur especially when used in high doses; tremor, headache, coma, and delirium have been reported and are associated with serum concentrations. Seizures may also occur. Posterior reversible encephalopathy syndrome (PRES) has been reported; symptoms (altered mental status, headache, hypertension, seizures, and visual disturbances) are reversible with dose reduction or discontinuation of therapy; stabilize blood pressure and reduce dose with suspected or confirmed PRES diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): PRCA has been reported in patients receiving tacrolimus. Use with caution in patients with risk factors for PRCA including parvovirus B19 infection, underlying disease, or use of concomitant medications associated with PRCA (eg, mycophenolate). Discontinuation of therapy should be considered with diagnosis of PRCA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution; utilize lowest recommended IV or oral dose; additional dose reductions may be necessary; severe hepatic impairment (Child-Pugh score &ge;10) may require decreased dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Due to potential for further nephrotoxicity, utilize lowest recommended IV or oral dose; additional dose reductions may be necessary. Delay initiation of therapy in kidney transplant patients if postoperative oliguria occurs; begin therapy no sooner than 6 hours and within 24 hours post-transplant, but may be delayed until renal function has recovered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Concomitant use with strong CYP3A inducers and/or inhibitors may alter tacrolimus whole blood concentrations, potentially leading to rejection and/or increased toxicity, respectively. Monitor tacrolimus whole blood trough concentrations closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Everolimus combination therapy: In liver transplantation, the tacrolimus dose and target range should be reduced to minimize the risk of nephrotoxicity when used in combination with everolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sirolimus combination therapy: Extended release tacrolimus in combination with sirolimus is not recommended in renal transplant patients; the safety and efficacy of immediate release tacrolimus in combination with sirolimus has not been established in this patient population. Concomitant use was associated with increased mortality, graft loss, and hepatic artery thrombosis in liver transplant patients, as well as increased risk of renal impairment, wound healing complications, and PTDM in heart transplant recipients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release: <b>[US Boxed Warning]: Astagraf XL was associated with increased mortality in female liver transplant recipients; the use of extended release tacrolimus is not approved for use in liver transplantation.</b> Mortality at 12 months was 10% higher in females who received extended release tacrolimus compared to females who received regular release tacrolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Each mL of injection contains polyoxyl 60 hydrogenated castor oil (HCO-60) (200 mg) and dehydrated alcohol USP 80% v/v. Anaphylaxis has been reported with the injection, use should be reserved for those patients not able to take oral medications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Oral formulations contain lactose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Error prevention: Immediate release and extended release capsules are <b>NOT</b> interchangeable or substitutable. The extended release formulation is a once-daily preparation; and immediate release formulation is intended for twice-daily administration. Serious adverse events, including organ rejection, may occur if inadvertently substituted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppressive therapy and organ transplantation in a facility appropriate for monitoring and managing therapy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Patients should not be immunized with live vaccines during or shortly after treatment and should avoid close contact with recently vaccinated (live vaccine) individuals. Inactivated vaccines may be administered (response may be diminished).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring of concentrations: Closely monitor tacrolimus levels to assist in dose adjustment, monitor compliance, prevent organ rejection, and reduce drug-related toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564168\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564169\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16051&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: Tacrolimus (Systemic) may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10 mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer tacrolimus simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May increase the absorption of Tacrolimus (Systemic). More specifically, the initial absorption rate may be increased, as alcohol may speed the release of tacrolimus from extended-release tablets. Management: Advise patients receiving extended-release tacrolimus (Astagraf XL or Envarsus XR brands) not to take the medication with alcoholic beverages.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of Tacrolimus (Systemic). Specifically, this increase in tacrolimus concentrations may occur during the first week of combined therapy. Asunaprevir may decrease the serum concentration of Tacrolimus (Systemic). Specifically, this decrease in tacrolimus concentrations may occur with continued prolonged combination therapy.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus doses will need to be substantially reduced, and the tacrolimus dosing interval will likely need to be prolonged with concurrent boceprevir. Follow tacrolimus concentrations closely and monitor patients for evidence of tacrolimus toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Dihydropyridine): May increase the serum concentration of Tacrolimus (Systemic).<b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Tacrolimus (Systemic).<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caspofungin: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cinacalcet: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clotrimazole (Oral): May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clotrimazole (Topical): May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: Tacrolimus (Systemic) may increase the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tacrolimus (Systemic). Management: Monitor clinical tacrolimus response closely and frequently monitor tacrolimus serum concentrations with concurrent use of any strong CYP3A4 inhibitor.  Tacrolimus dose reductions and/or prolongation of the dosing interval will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May decrease the serum concentration of Tacrolimus (Systemic). Specifically, this decrease in tacrolimus concentrations may occur with continued prolonged combination therapy. Daclatasvir may increase the serum concentration of Tacrolimus (Systemic). Specifically, this increase in tacrolimus concentrations may occur during the first week of combined therapy.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: Tacrolimus (Systemic) may enhance the QTc-prolonging effect of Dronedarone. Dronedarone may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor for increased serum tacrolimus concentrations, tacrolimus toxicity, and QTc interval prolongation if combined with dronedarone. Tacrolimus dose adjustments may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Tacrolimus (Systemic). Management: Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of tacrolimus may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efonidipine: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ertapenem: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate and Derivatives: Tacrolimus (Systemic) may enhance the nephrotoxic effect of Fenofibrate and Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Monitor tacrolimus concentrations closely and adjust oral tacrolimus dose as necessary when concomitantly administered with fluconazole.  Reduced doses of tacrolimus will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease the metabolism of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with itraconazole. Tacrolimus dose reductions will likely be required. The magnitude of this interaction may be greater in older patients.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose adjustment may be required when taken with ketoconazole due to elevated plasma concentrations of tacrolimus.  Monitor tacrolimus concentrations and clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LevoFLOXacin (Systemic): May enhance the QTc-prolonging effect of Tacrolimus (Systemic). LevoFLOXacin (Systemic) may increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Tacrolimus (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of Tacrolimus (Systemic). MiFEPRIStone may increase the serum concentration of Tacrolimus (Systemic). Management: Avoid tacrolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Reduce tacrolimus dose to approximately one-third of original dose when starting posaconazole. Tacrolimus blood concentrations should be monitored closely during and at discontinuation of posaconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the metabolism of Tacrolimus (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.<b> Exceptions: </b>Pantoprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Tacrolimus (Systemic). Management: Consider alternatives when possible.  If these combination are used, monitor for reduced tacrolimus concentrations/effects following rifamycin initiation/dose increase, or increased concentrations/effects following rifamycin discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions may be needed with concurrent ritonavir. Monitor tacrolimus concentrations closely to determine dose; doses of tacrolimus 0.5 mg to 1 mg every week may be adequate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Schisandra: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Reuptake Inhibitor/Antagonists: May decrease the metabolism of Tacrolimus (Systemic).<b> Exceptions: </b>TraZODone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: May enhance the adverse/toxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the adverse/toxic effect of Sirolimus. Sirolimus may decrease the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Tacrolimus (Systemic). Management: Significant tacrolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both tacrolimus concentrations and clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Tacrolimus (Systemic) may enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Temsirolimus may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofisopam: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: When starting voriconazole in patients already receiving tacrolimus, reduce tacrolimus dose to one-third of the original dose. Monitor tacrolimus blood levels closely.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564173\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Alcohol may increase the rate of release of extended-release tacrolimus and adversely affect tacrolimus safety and/or efficacy. Management: Avoid alcohol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: Food decreases rate and extent of absorption. High-fat meals have most pronounced effect (37% and 25% decrease in AUC, respectively, and 77% and 25%  decrease in C<sub>max</sub>, respectively, for immediately release and extended release formulations). Grapefruit juice, a CYP3A4 inhibitor, may increase serum level and/or toxicity of tacrolimus. Management: Administer with or without food (immediate release), but be consistent. Administer extended release on an empty stomach. Avoid concurrent use of grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559521\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559522\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Tacrolimus crosses the human placenta and is measurable in the cord blood, amniotic fluid, and newborn serum. Tacrolimus concentrations in the placenta may be higher than the maternal serum (Jain 1997). Infants with lower birth weights have been found to have higher tacrolimus concentrations (Bramham 2013). Transient neonatal hyperkalemia and renal dysfunction have been reported.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Tacrolimus pharmacokinetics are altered during pregnancy. Whole blood concentrations decrease as pregnancy progresses; however, unbound concentrations increase. Measuring unbound concentrations may be preferred, especially in women with anemia or hypoalbuminemia. If unbound concentration measurement is not available, interpretation of whole blood concentrations should account for RBC count and serum albumin concentration (Hebert 2013; Zheng 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, women who have had a kidney transplant should be instructed that fertility will be restored following the transplant but that pregnancy should be avoided for ~2 years. Tacrolimus may be used as an immunosuppressant during pregnancy. The risk of infection, hypertension, and pre-eclampsia may be increased in pregnant women who have had a kidney transplant (EPBG 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527366\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function, hepatic function, serum electrolytes (magnesium, phosphorus, potassium), glucose and blood pressure, measure 3 times/week for first few weeks, then gradually decrease frequency as patient stabilizes. Signs/symptoms of anaphylactic reactions during IV infusion should also be monitored. Patients should be monitored for hypersensitivity during the first 30 minutes of the infusion, and frequently thereafter. Monitor for QT prolongation; consider echocardiographic evaluation in patients who develop renal failure, electrolyte abnormalities, or clinical manifestations of ventricular dysfunction.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Whole blood concentrations should be used for monitoring (trough for oral therapy drawn typically within 30 minutes prior to the next dose); frequency varies depending on transplant type, time since transplantation, and clinical situation. Tacrolimus serum levels may be falsely elevated in infected liver transplant patients due to interference from beta-galactosidase antibodies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527367\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Limited data correlating serum concentration to therapeutic efficacy/toxicity; in solid organ transplant recipients, goal levels vary depending on patient risk factors, concomitant immunosuppression, and time post-transplant:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trough (whole blood ELISA): 5 to 20 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trough (HPLC): 0.5 to 1.5 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heart transplant: Typical whole blood trough concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Months 1 to 3 post-transplant: 10 to 20 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Months &ge;4 post-transplant: 6 to 18 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kidney transplant: Whole blood trough concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In combination with azathioprine:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Months 1 to 3 post-transplant: 7 to 20 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Months 4 to 12 post-transplant: 5 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In combination with mycophenolate mofetil/IL-2 receptor antagonist (eg, daclizumab): Months 1 to 12 post-transplant: 4 to 11 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (Astagraf XL): Adolescents &ge;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">With basiliximab induction:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Month 1 post-transplant: 7 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Months 2 to 6 post-transplant: 5 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;6 months post-transplant: 5 to 10 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Without induction:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Month 1 post-transplant: 10 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Months 2 to 6 post-transplant: 5 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;6 months post-transplant: 5 to 10 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liver transplant: Whole blood trough concentrations: Months 1 to 12 post-transplant: 5 to 20 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of graft-vs-host disease: 10 to 20 ng/mL (Uberti 1999); although some institutions use a lower limit of 5 ng/mL and an upper limit of 15 ng/mL (Przepiorka 1999; Yanik 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Suppresses cellular immunity (inhibits T-lymphocyte activation), by binding to an intracellular protein, FKBP-12 and complexes with calcineurin dependent proteins to inhibit calcineurin phosphatase activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564197\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Better in resected patients with a closed stoma; unlike cyclosporine, clamping of the T-tube in liver transplant patients does not alter trough concentrations or AUC; Oral: Incomplete and variable (5% to 67%); the rate and extent of absorption is decreased (27%) by food (particularly a high-fat meal). Oral absorption may be variable in stem cell transplant patients with mucositis due to the conditioning regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes to erythrocytes, lung, kidneys, pancreas, liver, heart, and spleen;  V<sub>d</sub>: Children: 2.6 L/kg (mean) ; Adults: 0.85 to 1.41 L/kg (mean) in liver and renal transplant patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~99% primarily to albumin and alpha-1 acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via CYP3A4 to eight possible metabolites (major metabolite, 31-demethyl tacrolimus, shows same activity as tacrolimus in vitro)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Children: 7% to 55%, Adults: 7% to 32%; Absolute: Unknown</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 7.7 to 15.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: Variable, 23 to 46 hours in healthy volunteers; 2.1 to 36 hours in transplant patients; prolonged in patients with severe impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Extended release: 38 &plusmn; 3 hours; prolonged in patients with severe hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 0.5 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~93%); urine (&lt;1% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: 7 to 103 mL/minute/kg (average: 30 mL/minute/kg); clearance higher in children</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527370\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>Dose conversion from cyclosporine to tacrolimus</i>: Very limited data: Based on data reported in 58 pediatric heart transplant recipients on stable doses, the following conversion factor has been suggested. <b>Note:</b> This is only applicable to patients already stabilized on a consistent dose (Notaro 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &lt;2 years: Use conversion factor of 60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents &ge;2 years: Use conversion factor of 42</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564281\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>1 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 1 mg/mL tacrolimus oral suspension may be made with immediate release capsules, sterile water, Ora-Plus, and Ora-Sweet. Pour the contents of six 5 mg capsules into a plastic amber prescription bottle. Add ~5 mL of sterile water and agitate bottle until drug disperses into a slurry. Add equal parts Ora-Plus and Ora-Sweet in sufficient quantity to make 30 mL. Store in plastic amber prescription bottles; label &quot;shake well.&quot; Stable for 4 months at room temperature (Elefante 2006).</p>\n    <div class=\"reference\">Elefante A, Muindi J, West K, et al, &ldquo;Long-Term Stability of a Patient-Convenient 1 mg/mL Suspension of Tacrolimus for Accurate Maintenance of Stable Therapeutic Levels,&rdquo; <i>Bone Marrow Transplant</i>. 2006, 37(8):781-784.<span class=\"pubmed-id\">16518428</span></div>\r\n\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>0.5 mg/mL Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 0.5 mg/mL tacrolimus oral suspension may be made with immediate release capsules and a 1:1 mixture of Ora-Plus and Simple Syrup, N.F. Mix the contents of six 5 mg tacrolimus capsules with quantity of vehicle sufficient to make 60 mL. Store in glass or plastic amber prescription bottles; label &quot;shake well.&quot; Stable for 56 days at room temperature (Esquivel 1996; Foster 1996).</p>\n    <div class=\"reference\">Esquivel C, So S, McDiarmid S, Andrews W, et al. Suggested Guidelines for the Use of Tacrolimus in Pediatric Liver Transplant Patients. <i>Transplantation.</i> 1996;61(5):847-848.<span class=\"pubmed-id\">8607198</span></div>\r\n\n    <div class=\"reference\">Foster JA, Jacobson PA, Johnson CE, et al, &ldquo;Stability of Tacrolimus in an Extemporaneously Compounded Oral Liquid (Abstract of Meeting Presentation),&rdquo; <i>American Society of Health-System Pharmacists Annual Meeting</i>, 1996, 53:P-52(E).<span class=\"pubmed-id\">9117806</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564279\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Astagraf XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $84.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $169.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $847.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Prograf Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $358.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $716.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $3,583.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tacrolimus Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $222.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $445.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $2,229.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Prograf Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (1 mL): $247.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Envarsus XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (30): $130.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $174.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $698.39</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390236\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adoport (GB);</li>\n      <li>Advagraf (BE, CN, CZ, DE, DK, EE, ES, FR, GB, HK, HR, IE, IS, LT, LU, LV, MT, NO, PH, QA, RO, SE, SI, SK, TH, TR, TW, VN);</li>\n      <li>Advahraf (UA);</li>\n      <li>Capexion (GB);</li>\n      <li>Cidimus (PH);</li>\n      <li>Envarsus (AT, CZ, DE, DK, EE, ES, FR, GB, GR, HR, HU, IE, LT, LV, NL, NO, PL, PT, SI);</li>\n      <li>Graceptor (JP);</li>\n      <li>Modigraf (GB, IE, LV);</li>\n      <li>Pangraf (IN, LK);</li>\n      <li>Panraf (JO);</li>\n      <li>Prograf (AE, AR, AT, AU, BB, BE, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KR, KW, LB, LY, MT, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, UY, VE, VN, YE);</li>\n      <li>Prograf XL (AU, CO);</li>\n      <li>Prograft (LU);</li>\n      <li>Prohraf (UA);</li>\n      <li>Regraf (LK);</li>\n      <li>T-Inmun (PY);</li>\n      <li>Tacgraf (LK);</li>\n      <li>Tacrobell (KR);</li>\n      <li>Tacrotec (PH);</li>\n      <li>Tagraf (PH);</li>\n      <li>Tarimus (KR);</li>\n      <li>Vingraf (LK, PH);</li>\n      <li>Vivadex (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asante-Korang A, Boyle GJ, Webber SA, et al, &ldquo;Experience of FK506 Immune Suppression in Pediatric Heart Transplantation: A Study of Long-Term Adverse Effects,&rdquo; <i>J Heart Lung Transplant</i>, 1996, 15(4):415-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/8732602/pubmed\" target=\"_blank\" id=\"8732602\">8732602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bock ME, Cohn RA, Ali FN. Treatment of childhood nephrotic syndrome with long-term, low-dose tacrolimus. <i>Clin Nephrol</i>. 2013;79(6):432-438.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/23380387/pubmed\" target=\"_blank\" id=\"23380387\">23380387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bramham K, Chusney G, Lee J, et al, &quot;Breastfeeding and Tacrolimus: Serial Monitoring in Breast-Fed and Bottle-Fed Infants,&quot; <i>Clin J Am Soc Nephrol</i>, 2013, Apr;8(4):563-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/23349333/pubmed\" target=\"_blank\" id=\"23349333\">23349333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doligalski CT, Liu EC, Sammons CM, Silverman A, Logan AT. Sublingual administration of tacrolimus: current trends and available evidence. <i>Pharmacotherapy</i>. 2014;34(11):1209-1219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/25251980/pubmed\" target=\"_blank\" id=\"25251980\">25251980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EBPG Expert Group on Renal Transplantation, &quot;European Best Practice Guidelines For Renal Transplantation. Section IV: Long-Term Management of the Transplant Recipient, IV.10. Pregnancy in Renal Transplant Recipients,&quot; <i>Nephrol Dial Transplant</i>, 2002, 17 Suppl 4:50-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/12091650/pubmed\" target=\"_blank\" id=\"12091650\">12091650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filler G, Webb NJ, Milford DV, et al, &quot;Four-Year Data After Pediatric Renal Transplantation: A Randomized Trial of Tacrolimus Vs Cyclosporin Microemulsion,&quot; <i>Pediatr Transplant</i>, 2005, 9(4):498-503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/16048603/pubmed\" target=\"_blank\" id=\"16048603\">16048603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French AE, Soldin SJ, Soldin OP, et al, &ldquo;Milk Transfer and Neonatal Safety of Tacrolimus,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(6):815-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/12773068/pubmed\" target=\"_blank\" id=\"12773068\">12773068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furlong T, Storb R, Anasetti C, et al, &quot;Clinical Outcome After Conversion to FK 506 (Tacrolimus) Therapy for Acute Graft-Versus-Host Disease Resistant to Cyclosporine or for Cyclosporine-Associated Toxicities,&quot; <i>Bone Marrow Transplant</i>, 2000, 26(9):985-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/11100278/pubmed\" target=\"_blank\" id=\"11100278\">11100278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardiner SJ and Begg EJ, &ldquo;Breastfeeding During Tacrolimus Therapy,&rdquo; <i>Obstet Gynecol</i>, 2006, 107(2 Pt 2):453-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/16449146/pubmed\" target=\"_blank\" id=\"16449146\">16449146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Groetzner J, Reichart B, Roemer U, et al, &quot;Cardiac Transplantation in Pediatric Patients: Fifteen-Year Experience of a Single Center,&quot; <i>Ann Thorac Surg</i>, 2005, 79(1):53-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/15620914/pubmed\" target=\"_blank\" id=\"15620914\">15620914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gulati A, Sinha A, Gupta A, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. <i>Kidney Int</i>. 2012;82(10):1130-1135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/22763815/pubmed\" target=\"_blank\" id=\"22763815\">22763815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hebert MF, Zheng S, Hays K, et al, &quot;Interpreting Tacrolimus Concentrations During Pregnancy and Postpartum,&quot; <i>Transplantation</i>, 2013, 95(7):908-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/23274970/pubmed\" target=\"_blank\" id=\"23274970\">23274970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15919450\"></a>Iwahori T, Takeuchi H, Matsuno N, et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. <i>Transplant Proc</i>. 2005;37(4):1739-1740.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/15919450/pubmed\" target=\"_blank\" id=\"15919450\">15919450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jahan A, Prabha R, Chaturvedi S, Mathew B, Fleming D, Agarwal I. Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. <i>Pediatr Nephrol</i>. 2015;30(11):1961-1967.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/26135137/pubmed\" target=\"_blank\" id=\"26135137\">26135137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jain A, Venkataramanan R, Fung JJ, et al, &ldquo;Pregnancy After Liver Transplantation Under Tacrolimus,&rdquo; <i>Transplantation</i>, 1997, 64(4):559-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/9293865/pubmed\" target=\"_blank\" id=\"9293865\">9293865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. <i>Kidney Int. Suppl.</i> 2012;139-274.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant</i>. 2009;9 Suppl 3:S1-155.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/19845597/pubmed\" target=\"_blank\" id=\"19845597\">19845597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim JS, Aviles DH, Silverstein DM, et al, &quot;Effect of Age, Ethnicity, and Glucocorticoid Use on Tacrolimus Pharmacokinetics in Pediatric Renal Transplant Patients,&quot; <i>Pediatr Transplant</i>, 2005, 9(2):162-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/15787787/pubmed\" target=\"_blank\" id=\"15787787\">15787787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kolb M, Offer K, Jin Z, et al. Risk factors for subtherapeutic tacrolimus levels after conversion from continuous intravenous infusion to oral in children after allogeneic hematopoietic cell transplantation. <i>Biol Blood Marrow Transplant</i>. 2016;22(5):957-961.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/26880117/pubmed\" target=\"_blank\" id=\"26880117\">26880117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDiarmid SV, Colonna JO, Shaked A, et al, &ldquo;Differences in Oral FK506 Dose Requirements Between Adults and Pediatric Liver Transplant Patients,&rdquo; <i>Transplantation</i>, 1993, 55(6):1328-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/7685933/pubmed\" target=\"_blank\" id=\"7685933\">7685933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menegaux F, Keeffe EB, Andrews BT, et al, &ldquo;Neurological Complications of Liver Transplantation in Adult Versus Pediatric Patients,&rdquo; <i>Transplantation</i>, 1994, 58(4):447-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/8073514/pubmed\" target=\"_blank\" id=\"8073514\">8073514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9165550\"></a>Min DI, Chen HY, Lee MK, Ashton K, Martin MF. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. <i>Pharmacotherapy</i>. 1997;17(3):457-463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/9165550/pubmed\" target=\"_blank\" id=\"9165550\">9165550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montini G, Ujka F, Varagnolo C, et al, &quot;The Pharmacokinetics and Immunosuppressive Response of Tacrolimus in Paediatric Renal Transplant Recipients,&quot; <i>Pediatr Nephrol</i>, 2006, 21(5):719-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/16550361/pubmed\" target=\"_blank\" id=\"16550361\">16550361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Occupational Safety and Health (NIOSH), &quot;NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.&quot; Available at <a href=\"http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf</a>. Accessed January 21, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolai S and Bunyavanich S. Hypersensitivity reaction to intravenous but not oral tacrolimus. <i>Transplantation</i>. 2012;94(9):e61-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/23128975/pubmed\" target=\"_blank\" id=\"23128975\">23128975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Notaro E, Brown L, Albers E, et al. Dose conversion factor between cyclosporine and tacrolimus in pediatric heart transplant recipients. <i>J Heart Lung Transplant</i>. 2014;33(7):766-768. doi: 10.1016/j.healun.2014.04.004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/24854566/pubmed\" target=\"_blank\" id=\"24854566\">24854566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Offer K, Kolb M, Jin Z, et al. Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation. <i>Biol Blood Marrow Transplant</i>. 2015;21(3):496-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/25536217/pubmed\" target=\"_blank\" id=\"25536217\">25536217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17391292\"></a>Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Tedesco-Silva H Jr, Medina-Pestana JO. Circadian and time-dependent variability in tacrolimus pharmacokinetics. <i>Fundam Clin Pharmacol</i>. 2007;21(2):191-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/17391292/pubmed\" target=\"_blank\" id=\"17391292\">17391292</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pennington CA, Park JM. Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. <i>Am J Health Syst Pharm</i>. 2015;72(4):277-284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/25631834/pubmed\" target=\"_blank\" id=\"25631834\">25631834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollock-Barziv SM, Dipchand AI, McCrindle BW, et al, &quot;Randomized Clinical Trial of Tacrolimus- Vs Cyclosporine-Based Immunosuppression in Pediatric Heart Transplantation: Preliminary Results at 15-Month Follow-Up,&quot; <i>J Heart Lung Transplant</i>, 2005, 24(2):190-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/15701436/pubmed\" target=\"_blank\" id=\"15701436\">15701436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Przepiorka D, Devine S, Fay J, et al, &quot;Practical Considerations in the Use of Tacrolimus for Allogeneic Marrow Transplantation,&quot; <i>Bone Marrow Transplant</i>, 1999, 24(10):1053-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/10578154/pubmed\" target=\"_blank\" id=\"10578154\">10578154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh RK, Humlicek T, Jeewa A, Fester K. Pediatric cardiac intensive care society 2014 consensus statement: pharmacotherapies in cardiac critical care immune therapy. <i>Pediatr Crit Care Med</i>. 2016;17(3 Suppl 1):S69-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/26945331/pubmed\" target=\"_blank\" id=\"26945331\">26945331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skeens M, Pai V, Garee A, et al. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. <i>Bone Marrow Transplant</i>. 2012;47(11):1415-1418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/22484323/pubmed\" target=\"_blank\" id=\"22484323\">22484323</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swenson JM, Fricker FJ, and Armitage JM, &quot;Immunosuppression Switch in Pediatric Heart Transplant Recipients: Cyclosporine to FK 506,&quot; <i>J Am Coll Cardiol</i>, 1995, 25(5):1183-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/7534779/pubmed\" target=\"_blank\" id=\"7534779\">7534779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taormina D, Abdallah HY, Venkataramanan R, et al, &quot;Stability and Sorption of FK 506 in 5% Dextrose Injection and 0.9% Sodium Chloride Injection in Glass, Polyvinyl Chloride, and Polyolefin Containers,&quot; <i>Am J Hosp Pharm</i>, 1992, 49(1):119-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/1373936/pubmed\" target=\"_blank\" id=\"1373936\">1373936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor DO, Barr ML, Meiser BM, Pham SM, Mentzer RM, Gass AL. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. <i>J Heart Lung Transplant</i>. 2001;20(7):734-738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/11448799/pubmed\" target=\"_blank\" id=\"11448799\">11448799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trompeter R, Filler G, Webb NJ, et al, &quot;Randomized Trial of Tacrolimus Versus Cyclosporin Microemulsion in Renal Transplantation,&quot; <i>Pediatr Nephrol</i>, 2002, 17(3):141-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/11956848/pubmed\" target=\"_blank\" id=\"11956848\">11956848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsapepas D, Saal S, Benkert S, et al. Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. <i>Pharmacotherapy</i>. 2013;33(1):31-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/23307542/pubmed\" target=\"_blank\" id=\"23307542\">23307542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uberti JP, Cronin S, and Ratanatharathorn V, &quot;Optimum Use of Tacrolimus in the Prophylaxis of Graft Versus Host Disease,&quot; <i>BioDrugs</i>, 1999, 11(5):343-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/18031144/pubmed\" target=\"_blank\" id=\"18031144\">18031144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Hooff J, Van der Walt I, Kallmeyer J, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. <i>Ther Drug Monit</i>. 2012;34(1):46-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/22249344/pubmed\" target=\"_blank\" id=\"22249344\">22249344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanik G, Levine JE, Ratanatharathorn V, et al, &quot;Tacrolimus (FK506) and Methotrexate as Prophylaxis for Acute Graft-Versus-Host Disease in Pediatric Allogeneic Stem Cell Transplantation,&quot; <i>Bone Marrow Transplant</i>, 2000, 26(2):161-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/10918426/pubmed\" target=\"_blank\" id=\"10918426\">10918426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zheng S, Easterling TR, Umans JG, et al, &quot;Pharmacokinetics of Tacrolimus During Pregnancy,&quot; <i>Ther Drug Monit</i>, 2012, 34(6):660-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-pediatric-drug-information/abstract-text/23007747/pubmed\" target=\"_blank\" id=\"23007747\">23007747</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16051 Version 197.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9559505\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9559510\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9559511\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10527287\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10527364\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9564277\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9559517\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F29038337\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50136484\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F21099222\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10527365\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133425\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9564175\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10527303\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9559508\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9559544\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9559526\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9559527\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9564168\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9564169\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F9564173\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9559521\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9559522\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10527366\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F10527367\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9564189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9564197\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10527370\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F9564281\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9564279\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390236\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16051|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tacrolimus-systemic-drug-information\" class=\"drug drug_general\">Tacrolimus (systemic): Drug information</a></li><li><a href=\"topic.htm?path=tacrolimus-systemic-patient-drug-information\" class=\"drug drug_patient\">Tacrolimus (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}